Stay updated with breaking news from Advances Publication. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Oblique Therapeutics AB (publ.), a biotechnology company focused on new antibody medicines for severe diseases with large unmet medical needs,...
GOTHENBURG, Sweden, Nov. 9, 2022 /PRNewswire/ -- Oblique Therapeutics AB (publ.), a biotechnology company focused on new antibody medicines for severe diseases with large unmet medical needs
Gothenburg, Sweden,9 November 2022 – Oblique Therapeutics AB (publ.), a biotechnology company focused on new antibody medicines for severe diseases with large unmet medical needs, is pleased to announce the confirmation of Christer Nordstedt MD.PhD. as Chief Executive Officer (CEO). Christer Nordstedt will assume the position on 1st December 2022.
/PRNewswire/ -- Press release - New Patent granted Oblique Therapeutics AB today announces that key aspects of its AbiProt® technology for discovering and...
Press release – New Patent granted Gothenburg, Sweden, 14 January 2022 – Oblique Therapeutics AB today announces that key aspects of its AbiProt® technology for discovering and developing pharmacologically tailored antibodies against clinically important targets has been granted by the USPTO as US Patent No. 11,161,901 B2. The technology uses artificially intelligent molecular probes and mass spectrometry to identify antibody binding sites on clinically relevant targets, many of which have been considered undruggable with antibodies. The AbiProt® proteomics technology from Oblique Thera...